Free Trial
NASDAQ:CDXC

ChromaDex (CDXC) Stock Price, News & Analysis

ChromaDex logo

About ChromaDex Stock (NASDAQ:CDXC)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$5.26
$8.55
52-Week Range
N/A
Volume
554,788 shs
Average Volume
809,214 shs
Market Capitalization
$611.50 million
P/E Ratio
787.29
Dividend Yield
N/A
Price Target
$9.03
Consensus Rating
Buy

Company Overview

ChromaDex Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
64th Percentile Overall Score

CDXC MarketRank™: 

ChromaDex scored higher than 64% of companies evaluated by MarketBeat, and ranked 397th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    ChromaDex has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    ChromaDex has received no research coverage in the past 90 days.

  • Read more about ChromaDex's stock forecast and price target.
  • Earnings Growth

    Earnings for ChromaDex are expected to grow by 200.00% in the coming year, from $0.04 to $0.12 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of ChromaDex is 787.29, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.22.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of ChromaDex is 787.29, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.19.

  • Short Interest

    There is no current short interest data available for CDXC.
  • Dividend Yield

    ChromaDex does not currently pay a dividend.

  • Dividend Growth

    ChromaDex does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for CDXC.
    • Insider Buying vs. Insider Selling

      In the past three months, ChromaDex insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      Only 9.64% of the stock of ChromaDex is held by insiders.

    • Percentage Held by Institutions

      Only 15.41% of the stock of ChromaDex is held by institutions.

    • Read more about ChromaDex's insider trading history.
    Receive CDXC Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for ChromaDex and its competitors with MarketBeat's FREE daily newsletter.

    CDXC Stock News Headlines

    A new rule goes live in July — and the banks are quietly cashing in
    A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
    ChromaDex to Present at the 37th Annual Roth Conference
    ChromaDex price target raised to $11 from $8 at H.C. Wainwright
    See More Headlines

    CDXC Stock Analysis - Frequently Asked Questions

    ChromaDex Co. (NASDAQ:CDXC) issued its earnings results on Thursday, October, 31st. The company reported $0.02 EPS for the quarter, beating analysts' consensus estimates of $0.01 by $0.02. The business had revenue of $25.58 million for the quarter, compared to the consensus estimate of $23.70 million. ChromaDex had a net margin of 1.62% and a trailing twelve-month return on equity of 4.85%.
    Read the conference call transcript
    .

    Shares of CDXC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that ChromaDex investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), AU Optronics (AUOTY) and DiamondRock Hospitality (DRH).

    Company Calendar

    Last Earnings
    10/31/2024
    Today
    7/02/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    Medicinals & botanicals
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:CDXC
    Employees
    120
    Year Founded
    N/A

    Price Target and Rating

    Average Stock Price Target
    $9.03
    High Stock Price Target
    $11.00
    Low Stock Price Target
    $8.00
    Consensus Rating
    Buy
    Rating Score (0-4)
    3.00
    Research Coverage
    3 Analysts

    Profitability

    Trailing P/E Ratio
    787.29
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    -$4.94 million
    Pretax Margin
    1.62%

    Debt

    Sales & Book Value

    Annual Sales
    $99.60 million
    Price / Cash Flow
    N/A
    Book Value
    $0.38 per share
    Price / Book
    N/A

    Miscellaneous

    Free Float
    69,020,000
    Market Cap
    $611.50 million
    Optionable
    Optionable
    Beta
    2.21

    Social Links

    7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

    Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

    Get This Free Report

    This page (NASDAQ:CDXC) was last updated on 7/3/2025 by MarketBeat.com Staff
    From Our Partners